Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2024 16:01 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D.,...
November 15, 2024 11:01 ET | Source: Arbutus Biopharma Corporation

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of...
August 08, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
June 12, 2024 16:01 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 06, 2024 11:15 ET | Source: Barinthus Biotherapeutics

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
May 13, 2024 08:00 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
April 18, 2024 16:10 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).
January 05, 2024 16:01 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
December 21, 2023 07:31 ET | Source: Barinthus Biotherapeutics

New partnership aims to advance vaccine against MERS coronavirus

CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to University of Oxford to develop VTP-500
November 09, 2023 16:01 ET | Source: Arbutus Biopharma Corporation

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then...